U.S. Markets close in 1 hr 52 mins

DIAGNOS Announces Today the Addition of a Strategic Partner in the Country of Mexico

BROSSARD, Quebec, Nov. 13, 2018 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today the addition of a strategic partner in the country of Mexico.  This agreement will enlarge the footprint coverage of DIAGNOS’ offering for monitoring diabetic patients through our first partner in that country.

“Today we all (my family and I), accepted unanimously to go with DIAGNOS in this adventure, we truly believe both of us will do great and together will achieve important objectives”, declares Quim. Sergio Galindo, founder and owner of Axmilab. “Mr. Andre Larente visited me in Monterrey city, my hometown at my brand new office, we clicked right away because we both are men of one vision: to provide the best diagnostic technology to prevent and leverage the health quality of people.” “I also met Mr. Georges Herbert Chairman of DIAGNOS Inc, during his visit to Mexico City. Very important reasons for me to partner with DIAGNOS, because I partner with true people”, finished Quim. Sergio Galindo.

“We express our gratitude and celebrate along with Axmilab family their decision to collaborate with us, the first step is to prepare ourselves for key projects in different states of Mexico”, mentions Mr. Guillermo Moreno, Vice President of DIAGNOS, Latin America.

Axmilab is a Mexican company with more than 24 years of experience by manufacturing and distributing products in the health sector. His founder, Quim. Sergio Galindo, has successfully driven the business since its conception in 1994, now with the support of his family, is growing exponentially as an example, they’ve been a supplier for IMSS (by winning contracts in the last 13 consecutive years in the diabetes area). Its dominant territory is Northern Mexico, headquarters is in Monterrey, N.L., also covering Mexico City, Sonora, Queretaro, Chiapas, Chihuahua, Durango, Jalisco, Yucatan, San Luis Potosi States among others. Since 1998, Axmilab has been working at all levels of Government, also represents major brands such as Roche, J&J, Licon, PKL, Alifax. 

DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.

Additional information is available at www.diagnos.com and www.sedar.com

For further information, please contact:

Mr. André Larente, President Josh Falle
DIAGNOS Inc. Momentum PR
Tel: 450-678-8882 ext. 224 Tel: 514-416-4656
alarente@diagnos.ca josh@momentumpr.com

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.